期刊
GLIA
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1002/glia.24465
关键词
Alzheimer's disease; microglia; phagocytosis; therapeutic targets
This review summarizes the current knowledge of the molecular mechanisms involved in microglial phagocytosis in Alzheimer's disease (AD) through a wide range of pre-clinical, post-mortem, ex vivo, and clinical studies. It also discusses the limitations regarding the detection of microglial phagocytosis in AD and the rationale of targeting microglial phagocytosis as a therapeutic strategy for preventing or slowing down the progression of AD.
Microglia are the resident phagocytes of the brain, where they primarily function in the clearance of dead cells and the removal of un- or misfolded proteins. The impaired activity of receptors or proteins involved in phagocytosis can result in enhanced inflammation and neurodegeneration. RNA-seq and genome-wide association studies have linked multiple phagocytosis-related genes to neurodegenerative diseases, while the knockout of such genes has been demonstrated to exert protective effects against neurodegeneration in animal models. The failure of microglial phagocytosis influences AD-linked pathologies, including amyloid ss accumulation, tau propagation, neuroinflammation, and infection. However, a precise understanding of microglia-mediated phagocytosis in Alzheimer's disease (AD) is still lacking. In this review, we summarize current knowledge of the molecular mechanisms involved in microglial phagocytosis in AD across a wide range of pre-clinical, post-mortem, ex vivo, and clinical studies and review the current limitations regarding the detection of microglia phagocytosis in AD. Finally, we discuss the rationale of targeting microglial phagocytosis as a therapeutic strategy for preventing AD or slowing its progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据